Zealand Pharma is a renowned Danish brand that specializes in developing next-generation peptide therapeutics. With a focus on peptide-based candidates, their research and development efforts aim to tackle metabolic diseases and change lives. Zealand Pharma's product pipeline includes promising candidates such as Glepaglutide for short bowel syndrome, Dasiglucagon for bihormonal artificial pancreas systems, Dasiglucagon for congenital hyperinsulinism, and BI 456906, a GLP-1/GLU dual agonist.

They also have an amylin analogue, ZP8396, in the works. Zealand Pharma's peptide platform is the foundation for their innovative therapies, designed to address specialty disease areas. With a commitment to transparency and responsibility, they provide comprehensive information about their corporate management, governance, and social responsibility.

Investors can find valuable information on their website, including stock information, financial reports, and events. Zealand Pharma is dedicated to improving lives through cutting-edge peptide therapeutics